Tumour vascularization: sprouting angiogenesis and beyond

Tumour angiogenesis is a fast growing domain in tumour biology. Many growth factors and mechanisms have been unravelled. For almost 30 years, the sprouting of new vessels out of existing ones was considered as an exclusive way of tumour vascularisation. However, over the last years several additional mechanisms have been identified. With the discovery of the contribution of intussusceptive angiogenesis, recruitment of endothelial progenitor cells, vessel co-option, vasculogenic mimicry and lymphangiogenesis to tumour growth, anti-tumour targeting strategies will be more complex than initially thought. This review highlights these processes and intervention as a potential application in cancer therapy. It is concluded that future anti-vascular therapies might be most beneficial when based on multimodal anti-angiogenic, anti-vasculogenic mimicry and anti-lymphangiogenic strategies.

[1]  S. Rafii,et al.  Placental growth factor reconstitutes hematopoiesis by recruiting VEGFR1+ stem cells from bone-marrow microenvironment , 2002, Nature Medicine.

[2]  N. Goldstein,et al.  Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors. , 1997, The American journal of pathology.

[3]  A. Karsan,et al.  Minimal Contribution of Marrow-Derived Endothelial Precursors to Tumor Vasculature1 , 2005, The Journal of Immunology.

[4]  W. Gerald,et al.  Effect of angiogenesis inhibition by Id loss and the contribution of bone-marrow-derived endothelial cells in spontaneous murine tumors. , 2003, Cancer cell.

[5]  R W Blamey,et al.  Prognostic value of lymphovascular invasion in women with lymph node negative invasive breast carcinoma. , 2006, European journal of cancer.

[6]  Thomas N. Sato,et al.  Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. , 1997, Science.

[7]  M. Rudek,et al.  Reversible sideroblastic anemia associated with the tetracycline analogue COL‐3 , 2001, American journal of hematology.

[8]  Oswald Wagner,et al.  Lymphoma-specific genetic aberrations in microvascular endothelial cells in B-cell lymphomas. , 2004, The New England journal of medicine.

[9]  M. Detmar,et al.  The rediscovery of the lymphatic system: old and new insights into the development and biological function of the lymphatic vasculature. , 2002, Genes & development.

[10]  M Buyse,et al.  Non-small-cell lung carcinoma tumor growth without morphological evidence of neo-angiogenesis. , 1997, The American journal of pathology.

[11]  J. Isner,et al.  Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization. , 1999, Circulation research.

[12]  L. Chin,et al.  Epigenetic transdifferentiation of normal melanocytes by a metastatic melanoma microenvironment. , 2005, Cancer research.

[13]  Tetsurou Matsumoto,et al.  Current and future status of prostate cancer chemoprevention , 2006, Expert review of anticancer therapy.

[14]  Arjun Deb,et al.  Integrin Profile and In Vivo Homing of Human Smooth Muscle Progenitor Cells , 2004, Circulation.

[15]  M. Hendrix,et al.  Prostatic tumor cell plasticity involves cooperative interactions of distinct phenotypic subpopulations: Role in vasculogenic mimicry , 2002, The Prostate.

[16]  E. Lee,et al.  Circulating numbers of endothelial progenitor cells in patients with gastric and breast cancer. , 2003, Cancer letters.

[17]  E. Rofstad,et al.  Hypoxia promotes lymph node metastasis in human melanoma xenografts by up-regulating the urokinase-type plasminogen activator receptor. , 2002, Cancer research.

[18]  Haruchika Masuda,et al.  Ischemia- and cytokine-induced mobilization of bone marrow-derived endothelial progenitor cells for neovascularization , 1999, Nature Medicine.

[19]  T. Iwanaga,et al.  Hemodynamics in vasculogenic mimicry and angiogenesis of inflammatory breast cancer xenograft. , 2002, Cancer research.

[20]  E. Manseau,et al.  Vascular Permeability Factor/Vascular Endothelial Growth Factor Induces Lymphangiogenesis as well as Angiogenesis , 2002, The Journal of experimental medicine.

[21]  P. Comoglio,et al.  Sema4D induces angiogenesis through Met recruitment by Plexin B1. , 2005, Blood.

[22]  P. Leder,et al.  The IP-10 chemokine binds to a specific cell surface heparan sulfate site shared with platelet factor 4 and inhibits endothelial cell proliferation , 1995, The Journal of experimental medicine.

[23]  D. Ribatti,et al.  Microvascular density, vascular endothelial growth factor immunoreactivity in tumor cells, vessel diameter and intussusceptive microvascular growth in primary melanoma. , 2005, Oncology reports.

[24]  K. Alitalo,et al.  A Recombinant Mutant Vascular Endothelial Growth Factor-C that Has Lost Vascular Endothelial Growth Factor Receptor-2 Binding, Activation, and Vascular Permeability Activities* , 1998, The Journal of Biological Chemistry.

[25]  S. Rafii,et al.  Mobilization of Endothelial and Hematopoietic Stem and Progenitor Cells by Adenovector‐Mediated Elevation of Serum Levels of SDF‐1, VEGF, and Angiopoietin‐1 , 2001, Annals of the New York Academy of Sciences.

[26]  M. Yoder,et al.  Unresolved questions, changing definitions, and novel paradigms for defining endothelial progenitor cells. , 2005, Blood.

[27]  E. Chavakis,et al.  High-Mobility Group Box 1 Activates Integrin-Dependent Homing of Endothelial Progenitor Cells , 2007, Circulation research.

[28]  K. Acharya,et al.  Role of placenta growth factor in cardiovascular health. , 2002, Trends in cardiovascular medicine.

[29]  A. Griffioen,et al.  Bactericidal/permeability-increasing protein (BPI) inhibits angiogenesis via induction of apoptosis in vascular endothelial cells. , 2000, Blood.

[30]  P. Pauwels,et al.  Absence of lymphangiogenesis in ductal breast cancer at the primary tumor site. , 2007, Cancer letters.

[31]  Shigeyoshi Itohara,et al.  Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis , 2000, Nature Cell Biology.

[32]  Zhong Chen,et al.  Does Vasculogenic Mimicry Exist in Astrocytoma? , 2005, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[33]  Y. Lotan,et al.  Lymphovascular invasion is independently associated with overall survival, cause-specific survival, and local and distant recurrence in patients with negative lymph nodes at radical cystectomy. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  G. Mann,et al.  Targeting lymphangiogenesis to prevent tumour metastasis , 2006, British Journal of Cancer.

[35]  P. Meltzer,et al.  Vascular channel formation by human melanoma cells in vivo and in vitro: vasculogenic mimicry. , 1999, The American journal of pathology.

[36]  M. Hendrix,et al.  Molecular determinants of ovarian cancer plasticity. , 2001, The American journal of pathology.

[37]  O. Fodstad,et al.  Association of insulin-like growth factor binding protein-3 expression with melanoma progression , 2006, Molecular Cancer Therapeutics.

[38]  Lars Holmgren,et al.  Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a lewis lung carcinoma , 1994, Cell.

[39]  Pamela F. Jones,et al.  Isolation of Angiopoietin-1, a Ligand for the TIE2 Receptor, by Secretion-Trap Expression Cloning , 1996, Cell.

[40]  T. Maione,et al.  Inhibition of development of murine melanoma lung metastases by systemic administration of recombinant platelet factor 4. , 1995, Journal of the National Cancer Institute.

[41]  D. Hanahan,et al.  Lymphatic zip codes in premalignant lesions and tumors. , 2006, Cancer research.

[42]  G. Yancopoulos,et al.  Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. , 1999, Science.

[43]  Paul S. Meltzer,et al.  Expression and functional significance of VE-cadherin in aggressive human melanoma cells: Role in vasculogenic mimicry , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[44]  C. Betsholtz,et al.  Endothelial/Pericyte Interactions , 2005, Circulation research.

[45]  Cun-Yu Wang,et al.  Notch signaling in the regulation of tumor angiogenesis. , 2006, Trends in cell biology.

[46]  D. Ruiter,et al.  Presence of a fluid-conducting meshwork in xenografted cutaneous and primary human uveal melanoma. , 2002, Investigative ophthalmology & visual science.

[47]  P. Meltzer,et al.  Cooperative interactions of laminin 5 gamma2 chain, matrix metalloproteinase-2, and membrane type-1-matrix/metalloproteinase are required for mimicry of embryonic vasculogenesis by aggressive melanoma. , 2001, Cancer research.

[48]  R. D'Amato,et al.  Genetic heterogeneity of the vasculogenic phenotype parallels angiogenesis; Implications for cellular surrogate marker analysis of antiangiogenesis. , 2005, Cancer cell.

[49]  Peter Carmeliet,et al.  Angiogenesis in life, disease and medicine , 2005, Nature.

[50]  M. Hendrix,et al.  Targeting the Tumor Microenvironment with Chemically Modified Tetracyclines: Inhibition of Laminin 5 γ2 Chain Promigratory Fragments and Vasculogenic Mimicry1Supported by NIH/National Cancer Institute Grants CA83137 (to R. E. B. S.), CA80318, CA88043-02S1, and CA59702 (to M. J. C. H.).1 , 2002 .

[51]  B. Döme,et al.  Vascularization of cutaneous melanoma involves vessel co‐option and has clinical significance , 2002, The Journal of pathology.

[52]  D. Yamashiro,et al.  Vascular remodeling and clinical resistance to antiangiogenic cancer therapy. , 2004, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[53]  H. Arakawa,et al.  Netrin-1 and its receptors in tumorigenesis , 2004, Nature Reviews Cancer.

[54]  K. Pantel,et al.  In vitro differentiation of endothelial cells from AC133-positive progenitor cells. , 1999, Blood.

[55]  N. Ferrara,et al.  The biology of VEGF and its receptors , 2003, Nature Medicine.

[56]  M. Hendrix,et al.  Targeting the tumor microenvironment with chemically modified tetracyclines: inhibition of laminin 5 gamma2 chain promigratory fragments and vasculogenic mimicry. , 2002, Molecular cancer therapeutics.

[57]  D. Curiel,et al.  Genetically modified CD34+ cells exert a cytotoxic bystander effect on human endothelial and cancer cells. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[58]  Michael Gnant,et al.  Prognostic Value of Lymphangiogenesis and Lymphovascular Invasion in Invasive Breast Cancer , 2004, Annals of surgery.

[59]  Dhara N. Amin,et al.  Tumor-Associated Endothelial Cells with Cytogenetic Abnormalities , 2004, Cancer Research.

[60]  D. Hanahan,et al.  The Hallmarks of Cancer , 2000, Cell.

[61]  B. Lane,et al.  Reversible posterior leukoencephalopathy syndrome and bevacizumab. , 2006, The New England journal of medicine.

[62]  A. Andres,et al.  Vascular remodelling during the normal and malignant life cycle of the mammary gland , 2001, Microscopy research and technique.

[63]  R. Kerbel Tumor angiogenesis: past, present and the near future. , 2000, Carcinogenesis.

[64]  M. Hendrix,et al.  Effects of angiogenesis inhibitors on vascular network formation by human endothelial and melanoma cells. , 2004, Journal of the National Cancer Institute.

[65]  D. Becker,et al.  Antisense targeting of basic fibroblast growth factor and dibroblast growth factor receptor-1 in human melanomas blocks intratumoral angiogenesis and tumor growth , 1997, Nature Medicine.

[66]  E C Nice,et al.  Isolated lymphatic endothelial cells transduce growth, survival and migratory signals via the VEGF‐C/D receptor VEGFR‐3 , 2001, The EMBO journal.

[67]  K. Alitalo,et al.  VEGF guides angiogenic sprouting utilizing endothelial tip cell filopodia , 2003, The Journal of cell biology.

[68]  R. Kalluri,et al.  Distinct Antitumor Properties of a Type IV Collagen Domain Derived from Basement Membrane* , 2000, The Journal of Biological Chemistry.

[69]  Thomas Hawighorst,et al.  Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis , 2001, Nature Medicine.

[70]  J. Isner,et al.  Transplantation of ex vivo expanded endothelial progenitor cells for therapeutic neovascularization. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[71]  J. Marx A Boost for Tumor Starvation , 2003, Science.

[72]  M. Karkkainen,et al.  Lymphatic vasculature: development, molecular regulation and role in tumor metastasis and inflammation. , 2004, Trends in immunology.

[73]  N. Itoh,et al.  Evolution of the Fgf and Fgfr gene families. , 2004, Trends in genetics : TIG.

[74]  S. Renninger,et al.  Minor Contribution of Bone Marrow‐Derived Endothelial Progenitors to the Vascularization of Murine Gliomas , 2003, Brain pathology.

[75]  Tatiana V. Petrova,et al.  Lymphangiogenesis in development and human disease , 2005, Nature.

[76]  G. Garcı́a-Cardeña,et al.  Dose-dependent response of FGF-2 for lymphangiogenesis. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[77]  B. Engelhardt,et al.  Multistep Nature of Microvascular Recruitment of Ex Vivo–expanded Embryonic Endothelial Progenitor Cells during Tumor Angiogenesis , 2003, The Journal of experimental medicine.

[78]  A. Mori,et al.  Tumour plasticity and extravascular circulation in ECV304 human bladder carcinoma cells. , 2006, Anticancer research.

[79]  M. Karkkainen,et al.  Vascular endothelial growth factor C promotes tumor lymphangiogenesis and intralymphatic tumor growth. , 2001, Cancer research.

[80]  P. Carmeliet,et al.  Angiogenesis in cancer and other diseases , 2000, Nature.

[81]  Michelle L. Varney,et al.  IL-8 Directly Enhanced Endothelial Cell Survival, Proliferation, and Matrix Metalloproteinases Production and Regulated Angiogenesis1 , 2003, The Journal of Immunology.

[82]  S. Hirakawa,et al.  Hepatocyte growth factor promotes lymphatic vessel formation and function , 2005, The EMBO journal.

[83]  Yihai Cao,et al.  Update on therapeutic neovascularization. , 2005, Cardiovascular research.

[84]  Eugene S. Kim,et al.  Potent VEGF blockade causes regression of coopted vessels in a model of neuroblastoma , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[85]  F. Liao,et al.  Migration of monocytes across endothelium and passage through extracellular matrix involve separate molecular domains of PECAM-1 , 1995, The Journal of experimental medicine.

[86]  Olivier Delattre,et al.  Tumor cell plasticity in Ewing sarcoma, an alternative circulatory system stimulated by hypoxia. , 2005, Cancer research.

[87]  N. Ferrara,et al.  The 16K fragment of prolactin specifically inhibits basal or fibroblast growth factor stimulated growth of capillary endothelial cells. , 1991, Endocrinology.

[88]  Steven A. Stacker,et al.  VEGF-D promotes the metastatic spread of tumor cells via the lymphatics , 2001, Nature Medicine.

[89]  M. Westphal,et al.  Inhibition of glioma angiogenesis and growth in vivo by systemic treatment with a monoclonal antibody against vascular endothelial growth factor receptor-2. , 2001, Cancer research.

[90]  A. Yayon,et al.  Effects of modulation of basic fibroblast growth factor on tumor growth in vivo. , 1993, Journal of the National Cancer Institute.

[91]  Yihai Cao,et al.  Insulin-like growth factors 1 and 2 induce lymphangiogenesis in vivo , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[92]  R. Folberg,et al.  Demonstrating circulation in vasculogenic mimicry patterns of uveal melanoma by confocal indocyanine green angiography , 2008, Eye.

[93]  P H Burri,et al.  Scanning electron microscope study of the developing microvasculature in the postnatal rat lung , 1986, The Anatomical record.

[94]  Napoleone Ferrara,et al.  Angiogenesis as a therapeutic target , 2005, Nature.

[95]  N. Yang,et al.  Tumor-derived vascular endothelial growth factor up-regulates angiopoietin-2 in host endothelium and destabilizes host vasculature, supporting angiogenesis in ovarian cancer. , 2003, Cancer research.

[96]  P. Corvol,et al.  Angiogenesis and vascular architecture in pheochromocytomas: distinctive traits in malignant tumors. , 2002, The American journal of pathology.

[97]  P. Dell’Era,et al.  Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis. , 2005, Cytokine & growth factor reviews.

[98]  K Anan,et al.  Vascular endothelial growth factor and platelet-derived growth factor are potential angiogenic and metastatic factors in human breast cancer. , 1996, Surgery.

[99]  P. Campochiaro,et al.  Angiopoietin-2 is required for postnatal angiogenesis and lymphatic patterning, and only the latter role is rescued by Angiopoietin-1. , 2002, Developmental cell.

[100]  B. Peters,et al.  Contribution of bone marrow–derived endothelial cells to human tumor vasculature , 2005, Nature Medicine.

[101]  A. Koch,et al.  Angiogenesis as a target in rheumatoid arthritis , 2003, Annals of the rheumatic diseases.

[102]  M. Turner,et al.  Drug-induced lupus associated with COL-3: report of 3 cases. , 2001, Archives of Dermatology.

[103]  P. Burri,et al.  Optimality in the developing vascular system: Branching remodeling by means of intussusception as an efficient adaptation mechanism , 2002, Developmental dynamics : an official publication of the American Association of Anatomists.

[104]  Takayuki Asahara,et al.  Isolation of Putative Progenitor Endothelial Cells for Angiogenesis , 1997, Science.

[105]  J. Berlin,et al.  Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. , 2004, The New England journal of medicine.

[106]  M. Hendrix,et al.  Focal adhesion kinase promotes the aggressive melanoma phenotype. , 2005, Cancer research.

[107]  Till Acker,et al.  Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions , 2001, Nature Medicine.

[108]  S. Rafii,et al.  Recruitment of Stem and Progenitor Cells from the Bone Marrow Niche Requires MMP-9 Mediated Release of Kit-Ligand , 2002, Cell.

[109]  C. Heeschen,et al.  Essential role of endothelial nitric oxide synthase for mobilization of stem and progenitor cells , 2003, Nature Medicine.

[110]  J. Mei,et al.  Tumor blood vessels formation in osteosarcoma: vasculogenesis mimicry. , 2004, Chinese medical journal.

[111]  K. Alitalo,et al.  Expression of the fms-like tyrosine kinase 4 gene becomes restricted to lymphatic endothelium during development. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[112]  M. Skobe,et al.  Molecular characterization of lymphatic endothelial cells , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[113]  Winnie S. Liang,et al.  A novel role for cyclooxygenase-2 in regulating vascular channel formation by human breast cancer cells , 2006, Breast Cancer Research.

[114]  R. Ji Lymphatic endothelial cells, tumor lymphangiogenesis and metastasis: New insights into intratumoral and peritumoral lymphatics , 2006, Cancer and Metastasis Reviews.

[115]  C. Walker Ophthalmology , 1859, Bristol medico-chirurgical journal.

[116]  N. Ferrara,et al.  The biology of vascular endothelial growth factor. , 1997, Endocrine reviews.

[117]  C. Ozcan,et al.  Reversible posterior leukoencephalopathy syndrome and bevacizumab. , 2006, The New England journal of medicine.

[118]  A. Griffioen,et al.  Molecular pathways of angiogenesis inhibition. , 2007, Biochemical and biophysical research communications.

[119]  H. Kurz,et al.  Platelet-derived growth factor-B induces transformation of fibrocytes into spindle-shaped myofibroblasts in vivo , 1998, Histochemistry and Cell Biology.

[120]  Baocun Sun,et al.  Hypoxia influences vasculogenic mimicry channel formation and tumor invasion-related protein expression in melanoma. , 2007, Cancer letters.

[121]  Toshio Ohhashi,et al.  PDGF-BB induces intratumoral lymphangiogenesis and promotes lymphatic metastasis. , 2004, Cancer cell.

[122]  R. Hebbel,et al.  Origins of circulating endothelial cells and endothelial outgrowth from blood. , 2000, The Journal of clinical investigation.

[123]  O. Kocher,et al.  Blood Markers for Vasculogenesis Increase with Tumor Progression in Patients with Breast Carcinoma , 2003, Cancer biology & therapy.

[124]  Thomas N. Sato,et al.  Leakage-resistant blood vessels in mice transgenically overexpressing angiopoietin-1. , 1999, Science.

[125]  M. Skobe,et al.  Therapeutic lymphangiogenesis with human recombinant VEGF‐C , 2002, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[126]  D J Ruiter,et al.  Quantitative immunohistological analysis of the microvasculature in untreated human glioblastoma multiforme. Computer-assisted image analysis of whole-tumor sections. , 1994, Journal of neurosurgery.

[127]  D. Newton,et al.  "Vasocrine" formation of tumor cell-lined vascular spaces: implications for rational design of antiangiogenic therapies. , 2003, Cancer research.

[128]  S. Rafii,et al.  Impaired recruitment of bone-marrow–derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth , 2001, Nature Medicine.

[129]  William Arbuthnot Sir Lane,et al.  Endostatin: An Endogenous Inhibitor of Angiogenesis and Tumor Growth , 1997, Cell.

[130]  Christian A. Rees,et al.  Molecular portraits of human breast tumours , 2000, Nature.

[131]  D. Jackson,et al.  LYVE-1, a New Homologue of the CD44 Glycoprotein, Is a Lymph-specific Receptor for Hyaluronan , 1999, The Journal of cell biology.

[132]  Y. Miyagi,et al.  Differential role of tissue factor pathway inhibitors 1 and 2 in melanoma vasculogenic mimicry. , 2003, Cancer research.

[133]  Wei Zhang,et al.  Vasculogenic mimicry is associated with high tumor grade, invasion and metastasis, and short survival in patients with hepatocellular carcinoma. , 2006, Oncology reports.

[134]  K. Alitalo,et al.  Adult bone marrow-derived cells recruited during angiogenesis comprise precursors for periendothelial vascular mural cells. , 2004, Blood.

[135]  R. Jain Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy , 2005, Science.

[136]  R. Folberg,et al.  The prognostic value of tumor blood vessel morphology in primary uveal melanoma. , 1993, Ophthalmology.

[137]  Ruslan Hlushchuk,et al.  Intussusceptive angiogenesis: Its emergence, its characteristics, and its significance , 2004, Developmental dynamics : an official publication of the American Association of Anatomists.

[138]  W. Gerald,et al.  Id1 and Id3 are required for neurogenesis, angiogenesis and vascularization of tumour xenografts , 1999, Nature.

[139]  Mark A. Hall,et al.  Hemostasis, Thrombosis, and Vascular Biology Materials and Methods Lacz and Platelet Endothelial Cell Adhesion Molecule 1 (pecam-1) Staining , 2022 .

[140]  E. Tschachler,et al.  Angiosarcomas express mixed endothelial phenotypes of blood and lymphatic capillaries: podoplanin as a specific marker for lymphatic endothelium. , 1999, The American journal of pathology.

[141]  D. Sane,et al.  Abnormal angiogenesis in diabetes mellitus , 2003, Medicinal research reviews.

[142]  Giovanni Martinelli,et al.  Continuous infusion of endostatin inhibits differentiation, mobilization, and clonogenic potential of endothelial cell progenitors. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[143]  K. Alitalo,et al.  Metastasis: Lymphangiogenesis and cancer metastasis , 2002, Nature Reviews Cancer.

[144]  M. Karkkainen,et al.  Abnormal lymphatic vessel development in neuropilin 2 mutant mice. , 2002, Development.

[145]  J. Partanen,et al.  Vascular endothelial growth factor C is required for sprouting of the first lymphatic vessels from embryonic veins , 2004, Nature Immunology.

[146]  J. Isner,et al.  VEGF contributes to postnatal neovascularization by mobilizing bone marrow‐derived endothelial progenitor cells , 1999, The EMBO journal.

[147]  K. Nakano,et al.  Angioarchitecture of Primary Oral Malignant Melanomas , 2002, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[148]  R. Jain,et al.  Intussusceptive microvascular growth in a human colon adenocarcinoma xenograft: a novel mechanism of tumor angiogenesis. , 1996, Microvascular research.

[149]  Peter J. Polverini,et al.  Regulation of the activity of a new inhibitor of angiogenesis by a cancer suppressor gene , 1989, Cell.

[150]  D. Hicklin,et al.  Effect of p53 Status on Tumor Response to Antiangiogenic Therapy , 2002, Science.

[151]  K. Alitalo,et al.  Angiopoietin-1 promotes LYVE-1-positive lymphatic vessel formation. , 2005, Blood.

[152]  Wei Zhang,et al.  Vasculogenic mimicry is associated with poor survival in patients with mesothelial sarcomas and alveolar rhabdomyosarcomas. , 2004, International journal of oncology.

[153]  Rakesh K Jain,et al.  Molecular regulation of vessel maturation , 2003, Nature Medicine.

[154]  S. Duan,et al.  Induction of tumor angiogenesis by Slit-Robo signaling and inhibition of cancer growth by blocking Robo activity. , 2003, Cancer cell.

[155]  M. Halford,et al.  Vascular Endothelial Growth Factor D Is Dispensable for Development of the Lymphatic System , 2005, Molecular and Cellular Biology.

[156]  U. Schumacher,et al.  PAS‐positive loops and networks as a prognostic indicator in cutaneous malignant melanoma , 2001, The Journal of pathology.

[157]  M. Skobe,et al.  Lymphatic endothelium , 2003, The Journal of cell biology.

[158]  W. Muller,et al.  CD99 plays a major role in the migration of monocytes through endothelial junctions , 2002, Nature Immunology.

[159]  Lars Holmgren,et al.  Dormancy of micrometastases: Balanced proliferation and apoptosis in the presence of angiogenesis suppression , 1995, Nature Medicine.

[160]  A. Pozzi,et al.  Soluble Eph A receptors inhibit tumor angiogenesis and progression in vivo , 2002, Oncogene.

[161]  Gerard C Blobe,et al.  Role of transforming growth factor Beta in human cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[162]  P. Burri,et al.  Evidence for intussusceptive capillary growth in the chicken chorio-allantoic membrane (CAM) , 1993, Anatomy and Embryology.

[163]  A. Bosserhoff,et al.  Functional implication of BMP4 expression on angiogenesis in malignant melanoma , 2006, Oncogene.

[164]  Amato J Giaccia,et al.  The hypoxic microenvironment of the skin contributes to Akt-mediated melanocyte transformation. , 2005, Cancer cell.

[165]  M. Hendrix,et al.  Embryonic and tumorigenic pathways converge via Nodal signaling: role in melanoma aggressiveness , 2006, Nature Medicine.

[166]  M. Kreuter,et al.  Semaphorin 3F, a chemorepulsant for endothelial cells, induces a poorly vascularized, encapsulated, nonmetastatic tumor phenotype. , 2004, The Journal of clinical investigation.

[167]  M. Hendrix,et al.  Angiogenesis: Vasculogenic mimicry and tumour-cell plasticity: lessons from melanoma , 2003, Nature Reviews Cancer.